This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Fibronectin 1 (FN1; FN)	<p>Mouse studies identified an FN1-targeting antibody-drug conjugate that could help treat cancer. A variant of the cytotoxic peptide cemadotin was conjugated to a human antibody against the tumor vascular protein FN1. In a mouse tumor model, the conjugate decreased tumor growth and increased survival compared with the peptide conjugated to a control antibody or unconjugated peptide. Next steps include generating conjugates with different therapeutic payloads and testing them in additional models of cancer.</p> <p>SciBX 5(3); doi:10.1038/scibx.2012.69 Published online Jan. 19, 2012</p>	Patent applications filed by Philogen S.p.A.; available for licensing	<p>Bernardes, G.J.L. <i>et al. Angew. Chem. Int. Ed.</i>; published online Dec. 15, 2011; doi:10.1002/anie.201106527</p> <p>Contact: Dario Neri, Swiss Federal Institute of Technology Zurich (ETHZ), Zurich, Switzerland e-mail: dario.neri@pharma.ethz.ch</p>